Takara Bio Inc. (4974.T)
JPY 1002.0
(-0.2%)
JPY 1002.0
(-0.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 23.9 Billion JPY | -7.29% |
| 2022 | 24.21 Billion JPY | 19.26% |
| 2021 | 20.3 Billion JPY | 13.34% |
| 2020 | 17.91 Billion JPY | 20.84% |
| 2019 | 14.82 Billion JPY | -2.57% |
| 2018 | 15.21 Billion JPY | 0.81% |
| 2017 | 15.09 Billion JPY | 9.81% |
| 2016 | 13.74 Billion JPY | 0.7% |
| 2015 | 13.65 Billion JPY | 18.49% |
| 2014 | 11.52 Billion JPY | 8.53% |
| 2013 | 10.61 Billion JPY | 13.82% |
| 2012 | 9.32 Billion JPY | 66.2% |
| 2011 | 5.61 Billion JPY | -1.54% |
| 2010 | 5.7 Billion JPY | -9.18% |
| 2009 | 6.27 Billion JPY | 1.54% |
| 2008 | 6.18 Billion JPY | -6.14% |
| 2007 | 6.58 Billion JPY | -3.81% |
| 2006 | 6.84 Billion JPY | 11.9% |
| 2005 | 6.11 Billion JPY | 14.1% |
| 2004 | 5.36 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.98 Billion JPY | -3.43% |
| 2023 Q4 | 6.2 Billion JPY | 7.47% |
| 2023 Q3 | 5.77 Billion JPY | -1.6% |
| 2023 Q2 | 5.86 Billion JPY | -3.35% |
| 2023 Q1 | 6.06 Billion JPY | -15.62% |
| 2023 FY | 22.45 Billion JPY | -7.29% |
| 2022 Q3 | 5.87 Billion JPY | 5.57% |
| 2022 FY | 24.21 Billion JPY | 19.26% |
| 2022 Q1 | 5.58 Billion JPY | -8.98% |
| 2022 Q2 | 5.56 Billion JPY | -0.32% |
| 2022 Q4 | 7.19 Billion JPY | 22.34% |
| 2021 Q2 | 4.75 Billion JPY | 2.72% |
| 2021 Q3 | 4.78 Billion JPY | 0.55% |
| 2021 FY | 20.3 Billion JPY | 13.34% |
| 2021 Q4 | 6.13 Billion JPY | 28.29% |
| 2021 Q1 | 4.63 Billion JPY | -15.17% |
| 2020 Q4 | 5.45 Billion JPY | 24.92% |
| 2020 Q2 | 4.08 Billion JPY | 1.85% |
| 2020 FY | 17.91 Billion JPY | 20.84% |
| 2020 Q1 | 4 Billion JPY | 2.3% |
| 2020 Q3 | 4.37 Billion JPY | 7.08% |
| 2019 FY | 14.82 Billion JPY | -2.57% |
| 2019 Q2 | 3.62 Billion JPY | -0.93% |
| 2019 Q1 | 3.66 Billion JPY | -1.35% |
| 2019 Q3 | 3.61 Billion JPY | -0.3% |
| 2019 Q4 | 3.91 Billion JPY | 8.26% |
| 2018 Q2 | 3.88 Billion JPY | 2.1% |
| 2018 Q4 | 3.71 Billion JPY | -2.52% |
| 2018 Q3 | 3.8 Billion JPY | -2.03% |
| 2018 Q1 | 3.8 Billion JPY | -3.35% |
| 2018 FY | 15.21 Billion JPY | 0.81% |
| 2017 Q3 | 3.68 Billion JPY | 1.71% |
| 2017 Q2 | 3.62 Billion JPY | -5.7% |
| 2017 Q1 | 3.84 Billion JPY | -2.36% |
| 2017 Q4 | 3.94 Billion JPY | 6.86% |
| 2017 FY | 15.09 Billion JPY | 9.81% |
| 2016 Q2 | 3.44 Billion JPY | 7.05% |
| 2016 Q3 | 3.14 Billion JPY | -8.79% |
| 2016 FY | 13.74 Billion JPY | 0.7% |
| 2016 Q4 | 3.93 Billion JPY | 25.22% |
| 2016 Q1 | 3.22 Billion JPY | -10.36% |
| 2015 Q2 | 3.45 Billion JPY | 7.82% |
| 2015 FY | 13.65 Billion JPY | 18.49% |
| 2015 Q4 | 3.59 Billion JPY | 5.87% |
| 2015 Q3 | 3.39 Billion JPY | -1.91% |
| 2015 Q1 | 3.2 Billion JPY | -3.81% |
| 2014 Q3 | 2.76 Billion JPY | 0.69% |
| 2014 Q4 | 3.33 Billion JPY | 20.83% |
| 2014 FY | 11.52 Billion JPY | 8.53% |
| 2014 Q1 | 2.68 Billion JPY | -6.05% |
| 2014 Q2 | 2.74 Billion JPY | 2.05% |
| 2013 Q3 | 2.61 Billion JPY | 0.54% |
| 2013 Q4 | 2.85 Billion JPY | 9.5% |
| 2013 FY | 10.61 Billion JPY | 13.82% |
| 2013 Q1 | 2.54 Billion JPY | 6.34% |
| 2013 Q2 | 2.59 Billion JPY | 1.88% |
| 2012 Q2 | 1.2 Billion JPY | 0.17% |
| 2012 Q4 | 2.39 Billion JPY | -46.9% |
| 2012 Q1 | 1.2 Billion JPY | -45.26% |
| 2012 FY | 9.32 Billion JPY | 66.2% |
| 2012 Q3 | 4.51 Billion JPY | 273.37% |
| 2011 Q3 | 1.13 Billion JPY | -0.26% |
| 2011 Q1 | 1.12 Billion JPY | -50.55% |
| 2011 Q4 | 2.2 Billion JPY | 93.76% |
| 2011 FY | 5.61 Billion JPY | -1.54% |
| 2011 Q2 | 1.14 Billion JPY | 1.15% |
| 2010 Q2 | 1.16 Billion JPY | 1.22% |
| 2010 FY | 5.7 Billion JPY | -9.18% |
| 2010 Q4 | 2.28 Billion JPY | 106.8% |
| 2010 Q3 | 1.1 Billion JPY | -5.4% |
| 2010 Q1 | 1.15 Billion JPY | -53.83% |
| 2009 Q2 | 1.27 Billion JPY | 0.95% |
| 2009 Q4 | 2.49 Billion JPY | 98.17% |
| 2009 Q3 | 1.25 Billion JPY | -1.02% |
| 2009 FY | 6.27 Billion JPY | 1.54% |
| 2009 Q1 | 1.26 Billion JPY | -48.45% |
| 2008 Q3 | 1.26 Billion JPY | 0.0% |
| 2008 Q2 | 1.26 Billion JPY | 0.0% |
| 2008 FY | 6.18 Billion JPY | -6.14% |
| 2008 Q4 | 2.44 Billion JPY | 92.59% |
| 2007 FY | 6.58 Billion JPY | -3.81% |
| 2006 FY | 6.84 Billion JPY | 11.9% |
| 2005 FY | 6.11 Billion JPY | 14.1% |
| 2004 FY | 5.36 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | -1761.075% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -4044.31% |
| GNI Group Ltd. | 9.32 Billion JPY | -156.427% |
| Linical Co., Ltd. | 2.7 Billion JPY | -783.671% |
| Trans Genic Inc. | 2.15 Billion JPY | -1006.802% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | -1503.115% |
| Soiken Holdings Inc. | 3.07 Billion JPY | -678.393% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | -1187.309% |
| AnGes, Inc. | 8.9 Billion JPY | -168.529% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -2434.777% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | -24.57% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -5688.276% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -2350.862% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | -831.035% |
| CanBas Co., Ltd. | 278 Million JPY | -8498.921% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -1994.11% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | -1214.943% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | -1390.557% |
| Kidswell Bio Corporation | 2.37 Billion JPY | -906.924% |
| PeptiDream Inc. | 9.68 Billion JPY | -146.767% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | -1119.275% |
| Ribomic Inc. | 1.1 Billion JPY | -2061.996% |
| SanBio Company Limited | 4.53 Billion JPY | -426.658% |
| Healios K.K. | 3.48 Billion JPY | -585.546% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -1970.167% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | -1691.355% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | -1603.287% |
| StemRIM | 2.07 Billion JPY | -1051.493% |
| CellSource Co., Ltd. | 1.96 Billion JPY | -1117.471% |
| FunPep Company Limited | 313.82 Million JPY | -7517.4% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -2395.271% |
| Stella Pharma Corporation | 963.98 Million JPY | -2379.81% |
| TMS Co., Ltd. | 943.25 Million JPY | -2434.315% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -2093.216% |
| Cuorips Inc. | 598.11 Million JPY | -3896.703% |
| K Pharma,Inc. | 543.94 Million JPY | -4294.77% |
| ReproCELL Incorporated | 1.51 Billion JPY | -1478.914% |
| PhoenixBio Co., Ltd. | 1.18 Billion JPY | -1919.02% |
| StemCell Institute Inc. | 1.16 Billion JPY | -1957.013% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | -1470.345% |
| CellSeed Inc. | 804.93 Million JPY | -2869.82% |